Use of Mellitor Sensor for Continuous Glucose Monitoring - An Ex-Vivo Study
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Most patients with diabetes mellitus have to measure their blood glucose levels quite often, in order to maintain a proper glycemic control. Current methods of self-monitoring of blood glucose are invasive, painful, uncomfortable, and only allow occasional, from time-to-time, measurements. Real-time continuous monitoring would provide a helpful tool for improvement of glycemic control, thus decreasing the incidence of hypoglycemia and improving glucose control. The Mellitor sensor is a new concept of continue glucose monitoring device. The Mellitor device is an implantable continuous glucose monitoring sensor that is intended for detection episodes of hyperglycemia and hypoglycemia in diabetic patients, and facilitates both acute and long-term therapy adjustments. This study was design in order to evaluate glucose measurement capabilities by the Mellitor sensor that is being developed. Transudate liquid samples, withdrawn in a clinical procedure and normally immediately disposed, will be used for glucose measurement by the Mellitor sensor.
Study Design
This study is an ex-vivo comparative study. 20 patients will be recruited for the study, according to patients' inflow and meeting eligibility criteria.
Study Goal
Study objective is to evaluate the feasibility of the Mellitor Sensor technology for glucose level measurement.
Study Endpoint
Mellitor technology feasibility will be established by comparing Mellitor glucose measurements results, based on transudate/exudates liquid withdrawal for other medical reasons, to "gold standard, Yellow Springs" glucose analyzer, or a comparable, calibrated and approved device using the same transudate/exudates liquid. Interdevice variability should be within 10%.
| Condition | Intervention |
|---|---|
|
Diabetes Mellitus |
Device: Mellitor device for glucose measurement |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Use of Mellitor Sensor for Continuous Glucose Monitoring - An Ex-Vivo Study |
- Mellitor technology feasibility will be established by comparing Mellitor glucose measurements results to "gold standard, Yellow Springs" glucose analyzer, or a comparable. Interdevice variability should be within 10%. [ Time Frame: during glucose measurements ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | October 2009 |
| Estimated Study Completion Date: | October 2010 |
| Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
Glucose measurements using "Mellitor" device.
|
Device: Mellitor device for glucose measurement
Glucose measurement using "Mellitor" device
|
|
Active Comparator: B
Glucose measurements conducted by using gold standard, "Yellow Springs" glucose analyzer
|
Device: Mellitor device for glucose measurement
Glucose measurement using "Mellitor" device
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male/Female aged 18 and up.
- Subject was scheduled for transudate/exudate liquid withdrawal.
- Subject able to comprehend and give informed consent for participation in this study.
- Signed Informed Consent Form
Exclusion Criteria:
- Known cognitive or psychiatric disorder.
- Subjects with HIV.
- Subject refuses to sign inform consent form.
Contacts and Locations| Contact: Hanna Levy, Dr. | (972)-4-638-8837 | hanna@qsitemed.com |
| Israel | |
| Hadassah Medical Organization | Not yet recruiting |
| Jerusalem, Israel, 91120 | |
| Contact: Hanna Levy, Dr. (972)-4-638-8837 hanna@qsitemed.com | |
| Principal Investigator: | Roi Eldor, MD | Hadassah Medical Organization, Jerusalem |
More Information
No publications provided
| Responsible Party: | Dr. Hanna Levy - study director, Melitor |
| ClinicalTrials.gov Identifier: | NCT00746642 History of Changes |
| Other Study ID Numbers: | MS-EV -1.0 |
| Study First Received: | September 3, 2008 |
| Last Updated: | June 2, 2009 |
| Health Authority: | Israel: Ethics Commission |
Keywords provided by Mellitor:
|
glucose measurements |
Additional relevant MeSH terms:
|
Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013